Telo Genomics Highlights New MRD Methodology at The 2025 International Myeloma Society Meeting

Executive Summary

• Telo Genomics Corp. announced the presentation of a poster abstract on minimal residual disease (MRD) during the 22nd International Myeloma Society Annual Meeting in Toronto.
• The presentation, led by Laboratory Director Dr. Yulia Shifrin, details a new workflow for MRD evaluation combining CTC enumeration with the TeloView® 3D telomere profiling platform.
• The abstract will be published as a special supplement to the Clinical Lymphoma, Myeloma, & Leukemia Journal and made available on the Company website.

Key Details

• Event: 22nd International Myeloma Society Annual Meeting (Toronto, Canada, September 17-20, 2025).
• Presenter: Dr. Yulia Shifrin, Laboratory Director of Telo Genomics.
• Abstract Title: "3D Telomere Profiling of MRD in Liquid Biopsy as a Predictive Marker of Disease Stability or Progression".
• Technology Workflow: The presentation describes a workflow combining enumeration and immunophenotyping of individual Multiple Myeloma (MM) Circulating Tumor Cells (CTCs) with the TeloView® 3D telomere profiling platform.
• Methodology Advantage: Evaluation of CTCs from peripheral blood (liquid biopsy) is highlighted as a less invasive biomarker allowing for continuous patient monitoring, offering functional and biologically actionable data on disease cells beyond simple enumeration.
• Publication: Abstract to be published as a special supplement to the Clinical Lymphoma, Myeloma, & Leukemia Journal.
• Market Context: The release notes the FDA's Oncologic Drugs Advisory Committee (ODAC) unanimous vote in April 2024 to accept MRD as a clinical endpoint for accelerated approval of new multiple myeloma therapies.
• Market Size: The global MRD testing market is projected to reach USD 4.1 billion by 2032.
• Target Market: The total addressable market for Multiple Myeloma (MM) assays is estimated at over 750,000 tests per year in the US.
• Company Background: Telo Genomics has substantiated its proprietary technology in 160+ peer-reviewed publications and 30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Its lead application, Telo-MM, is being developed for Multiple Myeloma.

Notable Quotes

• No direct quotes from the CEO or President were included in the release text.